Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
29 June 2017Website:
http://www.aileronrx.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 05 Jul 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
ALRN Latest News
AUSTIN, Texas , July 1, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the Company is set to join the Russell Microcap® Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024. The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks as of Tuesday, April 30th, ranking them by total market capitalization.
After losing some value lately, a hammer chart pattern has been formed for Aileron Therapeutics, Inc. (ALRN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
What type of business is Aileron Therapeutics?
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
What sector is Aileron Therapeutics in?
Aileron Therapeutics is in the Healthcare sector
What industry is Aileron Therapeutics in?
Aileron Therapeutics is in the Biotechnology industry
What country is Aileron Therapeutics from?
Aileron Therapeutics is headquartered in United States
When did Aileron Therapeutics go public?
Aileron Therapeutics initial public offering (IPO) was on 29 June 2017
What is Aileron Therapeutics website?
https://www.aileronrx.com
Is Aileron Therapeutics in the S&P 500?
No, Aileron Therapeutics is not included in the S&P 500 index
Is Aileron Therapeutics in the NASDAQ 100?
No, Aileron Therapeutics is not included in the NASDAQ 100 index
Is Aileron Therapeutics in the Dow Jones?
No, Aileron Therapeutics is not included in the Dow Jones index
When does Aileron Therapeutics report earnings?
The next expected earnings date for Aileron Therapeutics is 09 August 2024